This site uses cookies.
Some of these cookies are essential to the operation of the site,
while others help to improve your experience by providing insights into how the site is being used.
For more information, please see the ProZ.com privacy policy.
Scientist-turned-translator with 15 years of experience providing translations for the medical and scientific sectors.
Account type
Freelance translator and/or interpreter, Verified site user
Data security
This person has a SecurePRO™ card. Because this person is not a ProZ.com Plus subscriber, to view his or her SecurePRO™ card you must be a ProZ.com Business member or Plus subscriber.
Affiliations
This person is not affiliated with any business or Blue Board record at ProZ.com.
Services
Translation
Expertise
Specializes in:
Medical: Pharmaceuticals
Medical: Instruments
Medical: Cardiology
Medical: Oncology
Medical: Health Care
Science (general)
Medical (general)
Biology (-tech,-chem,micro-)
Genetics
Also works in:
Zoology
Medical: Dentistry
Chemistry; Chem Sci/Eng
More
Less
Rates
French to English - Standard rate: 0.09 EUR per word / 27 EUR per hour German to English - Standard rate: 0.09 EUR per word / 27 EUR per hour Luxembourgish to English - Standard rate: 0.09 EUR per word / 27 EUR per hour
German to English: Sample translation 1 German into English General field: Medical
Source text - German Die verbesserte Therapie und Prophylaxe von Herz-Kreislauf-Erkrankungen hat wie kein anderer Bereich der Medizin zum Anstieg der Lebenserwartung beigetragen. Dennoch bleiben viele kardiologische Krankheiten schlecht therapierbar, und Standardtherapien nutzen nur einer Minderheit von Patienten oderverursachen mehr Nebenwirkungen als Nutzen. Personalisierte Ansätze versprechen neue Lösungswege. Die seltenen monogenen Herz-Kreislauf-Erkrankungen sind hierfür paradigmatisch und lassen sich heute in Einzelfällen „mutationsspezifisch“ behandeln. Dennoch sind die Erfolge insgesamt noch bescheiden. Das „next generation sequencing“ wird die Identifizierung krankheitsverursachender Mutationen erleichtern. Zellkulturmodelle auf der Basis induzierter pluripotenter Stammzellen lassen eine individuelle Testung pharmakologischer oder gentherapeutischer Therapieansätze erwarten. Gegenwärtig noch von untergeordneter klinischer Bedeutung istdiegenetische Testung bei multifaktoriellen kardiovaskulären Volkskrankheiten. Biomarker haben dagegen das Potenzial, Individuen mit erhöhtem kardiovaskulärem Risiko zu identifizieren. Individualisierte, biomarkerge führte Therapien stellen eine attraktive Option für die Zukunft dar. Dafür ist die troponingesteuerte Therapie akuter Koronarsyndrome erfolgreiches Beispiel. Schließlich ist die individuelle Reaktion auf Arzneimittel teilweise genetisch determiniert und lässt sich mithilfe genetischer Analysen besser vorhersagen. Praktische Beispiele in der kardiovaskulären Medizin sind Warfarin und hohe Dosen von Simvastatin. Zusammengefasst werden personalisierte Ansätze in der kardiovaskulären Medizin sicher zunehmen. Dies erfordert die Entwicklung robusterer Methoden und Forschungen, die den tatsächlichen praktischen Nutzen der neuen Erkenntnisse auf den Prüfstand stellen.
Translation - English
Unlike any other field of medicine, the improved treatment and prevention of cardiovascular diseases has contributed to increased life expectancy. However, many cardiac diseases remain poorly treatable and standard therapies benefit only a minority of patients or cause more side effects than benefits. Personalised approaches promise new solutions. The rare monogenic cardiovascular diseases are paradigmatic of this and can today be treated according to the specific mutation in individual cases. Nevertheless, overall success is still modest. Next-generation sequencing will facilitate the identification of pathogenic mutations. Tissue culture models based on induced pluripotent stem cells offer individual testing of pharmacological or gene therapy approaches. Genetic testing is currently of minor clinical importance in the case of multifactorial cardiovascular diseases. In contrast, biomarkers have the potential to identify individuals with increased cardiovascular risk. Individualised, biomarker-led therapies are an attractive option for the future. Troponin-controlled therapy of acute coronary syndromes is a successful example. Finally, the individual response to drugs is partly genetically determined and can be better predicted using genetic analyses. Practical examples in cardiovascular medicine are warfarin and high doses of simvastatin. In summary, personalised approaches to cardiovascular medicine are certain to increase. This will require the development of more robust methods and research studies that examine the true practical benefits of new research findings.
German to English: Sample translation 2 German into English General field: Medical
Source text - German Eine 78-jährige Frau mit arteriellem Hypertonus, koronarer Herzkrankheit und Diabetes mellitus Typ II in der Anamnese rief wegen einer zunehmenden Ruhedyspnoe, die seit 1 Woche bestand, den Rettungsdienst. Zeichen für einen Atemwegsinfekt lagen nicht vor. Pektanginöse Beschwerden wie thorakale Schmerzen wurden ebenfalls nicht beobachtet. Neben der Dyspnoe klagte die Patientin über Inappetenz, gastrointestinale Beschwerden im Sinne von Übelkeit, Bauchschmerzen und Durchfällen sowie über ein allgemeines Schwächegefühl. Obwohl sie sonst altersentsprechend mobil war, hatte sie seit Tagen das Bett nicht verlassen. Bei einer täglichen Trinkmenge von ca. 3l hatte sie wenig Urin ausgeschieden. Den Rettungsassistenten gegenüber äußerte die Patientin, dass die Beschwerden sich zeitgleich mit einer Umstellung ihrer oralen antidiabetischen Medikation entwickelt hätten. Nachdem im Vorfeld diätetische Behandlungsansätze sowie eine Einstellung der Blutzuckerkrankheit mit Sulfonylharnstoff versucht worden waren, hatte der Hausarzt die orale Medikation 14 Tage zuvor auf Metformin (2-mal 1000mg/d) umgestellt. Außerdem nahm die Patientin kreislaufwirksame Medikamente wie Isosorbiddinitrat, Ramipril und Verapamil sowie das Ulkustherapeutikum Pantoprazol in den üblichen Dosierungen ein. Aufgrund der Gesamtkonstellation entschloss sich die Besatzung des RTW, die Patientin ins nächstgelegene Krankenhaus zu bringen.
Translation - English A 78-year-old woman with a history of high blood pressure, coronary heart disease and type II diabetes mellitus called the emergency services due to worsening dyspnoea at rest, which had persisted for 1 week. There were no signs of a respiratory infection. Angina-related symptoms, such as chest pain, were also not observed. In addition to the dyspnoea, the patient complained of a loss of appetite, gastrointestinal disorders (consisting of nausea, abdominal pain and diarrhoea), as well as a general feeling of malaise. Although she was otherwise age-appropriately mobile, she had not left her bed for days. With a daily fluid intake of approximately 3 litres, she had passed little urine. The patient told the paramedics that the complaints had developed at the same time as a change to her oral antidiabetic medication. After dietary treatment approaches as well as control of the diabetes with sulfonylurea had been attempted previously, the family doctor had changed the oral medication 14 days previously to metformin (2-times 1000 mg/day). In addition, the patient was taking the cardiovascular drugs isosorbide dinitrate, ramipril and verapamil, as well as the antiulcer drug pantoprazole, at the usual doses. Given the general clinical picture, the ambulance crew decided to take the patient to the nearest hospital.
German to English: Sample translation 3 German into English General field: Medical
Source text - German Bei klinisch vorhandenen Muskelschmerzen, einer massiven Erhöhung der CK im Serum und Myoglobulinurie liegt eine Rhabdomyolyse vor. Ursachen können neben Trauma, myotoxischen Medikamenten, Alkohol-, Drogenkonsum und Infektionen auch endokrine Stoff wechselstörungen oder Autoimmunerkrankungen sein. Auftretende Komplikationen sind beispielsweise akutes Nierenversagen und Kompartmentsyndrom. Das frühzeitige Erkennen der Ursache und deren Behebung und eine adäquate symptomatische Therapie verhindern schwerwiegende Komplikationen.
Wir präsentieren den klinischen Fall einer 44-jährigen Patientin, die sich mit dem Leitsymptom Myalgie vorstellte. Bei CK-Werten bis 8 830 IU/l. Begleitend zeigte sich ein Perikarderguss, ein Myxödem der Stimmlippen und im Verlauf trat eine Verschlechterung der Nierenfunktion auf. Unter L-Thyroxin Substitution und Volumensubstitution waren die Beschwerden rückläufig. Als Ursache diagnostizierten wir eine Hashimoto-Thyreoiditis.
Eine isolierte Hypothyreose als Ursache einer Rhabdomyolyse ist selten. In der Literaturfinden sich häufig auslösende Kofaktoren in der Anamnese, vor allem eine Therapie mit HMG-CoA-Reduktase-Hemmern.
Bei Myalgien und CK-Erhöhung als Leitsymptom muss als Ursache neben anderen Auslösern an eine Hashimoto-Thyreoiditis gedacht werden. Durch Hormonsubstitution und adäquate symptomatische Therapie können Komplikationen vermieden werden.
Translation - English
Clinical signs of myalgia, a massive increase in serum CK levels and myoglobinuria are indicative of rhabdomyolysis. In addition to trauma, causes can include myotoxic drugs, alcohol and drug misuse, infections and also endocrine metabolic disorders or autoimmune diseases. Complications include acute renal failure and compartment syndrome. Early identification of the cause and its correction, as well as appropriate symptomatic treatment, prevents serious complications.
Here we present the clinical case of a 44-year-old female patient who presented with the primary symptom of myalgia with CK values up to 8,830 IU/L. This was accompanied by pericardial effusion, vocal cord myxoedema and, as the condition progressed, worsening renal function. The symptoms improved with L-thyroxine substitution and volume replacement treatment. We diagnosed Hashimoto's thyroiditis as the cause.
Isolated hypothyroidism as a cause of rhabdomyolysis is rare. In the literature, there are often triggering cofactors in the medical history, especially treatment with HMG-CoA reductase inhibitors.
In the case of myalgia and CK increase as cardinal symptoms, in addition to other triggers, Hashimoto's thyroiditis must be considered as a potential cause. Hormone replacement therapy and appropriate symptomatic treatment can help avoid complications.
French to English: Sample translation 1 French into English General field: Medical
Source text - French Le 5-fluorouracile (5-FU) est une molécule très largement utilisée pour le traitement des cancers digestifs. Son métabolisme dépend essentiellement de la dihydropyrimidine déshydrogénase (DPD). Les patients présentant un déficit en cette enzyme sont à haut risque de présenter des effets indésirables graves lors d’un traitement par 5-FU. Notre objectif était d’évaluer la tolérance du 5-FU chez des patients présentant un déficit en DPD et pour lesquels une adaptation de dose avait été réalisée suivant une approche pharmacocinétique. Matériel et méthode : une analyse rétrospective des dossiers de patients présentant un déficit en DPD a été réalisée. Le deficit en DPD a été diagnostiqué par le laboratoire d’oncopharmacogénétique suivant une analyse multiparamétrique. Des ajustements de dose de 5-FU ont été suggérés par ce laboratoire en calculant la clairance plasmatique après la première administration de 5-FU. La dose proposée par le laboratoire et la dose de 5-FU réellement prescrite ont été comparées pour chaque patient et chaque cycle de chimiothérapie. Les données cliniques et biologiques de tolérance du traitement ont été recueillies. Résultats : les dossiers de 11 patients ont été analysés. Les patients ont été traités principalement pour des cancers colorectaux en situation adjuvante ou métastatique. Les doses de 5-FU en bolus et en perfusion continue suivaient les préconisations du laboratoire dans, respectivement, 84 % et 53 % des cas. Deux patients ont présenté une toxicité hématologique de grade 3 et de grade 4 ayant motivé l’arrêt définitif du traitement par 5-FU. Pour ces deux patients, le déficit d’activité de la DPD n’avait pas été recherché avant de débuter le traitement. Conclusion : cette étude a montré que le 5-FU était bien toléré chez les patients avec un déficit en DPD pour lesquels une adaptation de dose a été réalisée. Une approche pharmacocinétique est utile pour prévenir les effets indésirables du 5-FU chez des patients présentant un déficit en DPD.
Translation - English
5-fluorouracil (5-FU) is a drug that is very widely used for the treatment of cancers of the digestive system. Its metabolism depends primarily on dihydropyrimidine dehydrogenase (DPD). Patients presenting with a deficiency in this enzyme are at high risk of presenting with serious adverse effects during treatment with 5-FU. Our objective was to evaluate the safety of 5-FU in patients presenting with a deficiency in DPD and for whom a dose adjustment had been made using a pharmacokinetic approach. Materials and methods: A retrospective analysis of the medical records of patients presenting with a DPD deficiency was performed. The DPD deficiency was diagnosed by the oncopharmacogenetics laboratory using a multi-parametric analysis. 5-FU dosage adjustments were suggested by this laboratory by calculating the plasma clearance rate after the first administration of 5-FU. The dose suggested by the laboratory and the dose of 5-FU actually prescribed were compared for each patient and each cycle of chemotherapy. Clinical and laboratory treatment safety data were gathered. Results: The medical records of 11 patients were analysed. Patients primarily received adjuvant treatment for colorectal cancer or were treated in the context of metastases. The doses of 5-FU, as a bolus and as a continuous infusion, followed laboratory recommendations in 84% and 53% of cases, respectively. Two patients presented with grade 3 and grade 4 haemotoxicity, resulting in the permanent end of treatment with 5-FU. For these two patients, the DPD activity deficiency had not been assessed prior to starting treatment. Conclusions: This study showed that 5-FU was well-tolerated in patients with a DPD deficiency for whom a dosage adjustment had been made. A pharmacokinetic approach is useful in preventing the adverse effects of 5-FU in patients presenting with a DPD deficiency.
French to English: Sample translation 2 French into English General field: Medical
Source text - French L'héparine standard [1] et les héparines de bas poids moléculaire (HBPM) utilisées à doses préventives [2] peuvent induire des hypoaldostéronismes asymptomatiques ou se traduisant par une hyperkaliémie avec ou sans hyponatrémie. Cet hypoaldostéronisme bien qu'inconstant [2, 3] et en règle sans conséquences cliniques ou ioniques, mérite d'être souligné du fait de sa gravité potentielle. Nous rapportons 4 observations d'hypoaldostérisme survenues au cours d'un traitement par HBPM et caractérisées par des taux d'aldostérone plasmatique indétectables.
Il s'agit de 3 femmes et d' I homme, d'âge moyen (74 ± 4 ans) recevant Fraxiparine (3300 unités anti-Xa/24 h) (3 cas) ou de l'énoxaparine (2200 unités anti-Xa/24 h) (1 cas) à doses préventives. Les malades avaient un régime normosodé. Aucun n'avait de diabète, d'hypertension artérielle, d'insuffisance rénale ni de traitement associé pouvant interférer (diurétiques, inhibiteurs de l'enzyme de conversion, chlorpropamide...). Les paramètres mesurés étaient les concentrations d'aldostérone, de rénine, de cortisol ainsi que la natrémie et la kaliémie. Les dosages ont été réalisés au repos le matin avant la mise en œuvre du traitement (JO), 4 jours plus tard (J4), et 3 jours après la fin de celui-ci (J+3), l'arrêt étant justifié par des motifs médicaux.
Translation - English Standard heparin [1] and low-molecular-weight heparins (LMWHs) used at prophylactic doses [2] can induce asymptomatic hypoaldosteronism or manifest as hyperkalaemia with or without hyponatraemia. This hypoaldosteronism, although rare [2, 3] and, as a rule, without clinical or ionic consequences, deserves to be highlighted due to its possible severity. We report on 4 cases of hypoaldosteronism occurring during treatment with LMWH and characterised by undetectable levels of plasma aldosterone.
These involve 3 women and 1 man (average age: 74 ± 4 years) receiving fraxiparine (3300 units of anti-Xa/24 h) (3 cases) or enoxaparin (2200 units of anti-Xa/24 h) (1 case) at prophylactic doses. The patients were on a normal-sodium diet. None of them had diabetes, hypertension, renal failure or were receiving potentially interfering concomitant treatments (diuretics, ACE inhibitors, chlorpropamide, etc.). The parameters measured were the concentrations of aldosterone, rennin and cortisol, as well as blood sodium and potassium. The assays were performed at rest in the morning before start of treatment (D0), 4 days later (D4) and 3 days after the end of treatment (D+3), with the end of treatment being justified for medical reasons.
French to English: Sample translation 3 French into English
Source text - French Les effets secondaires thyroïdiens du lithium sont fréquents : goitres, hypothyroïdies. A l'inverse, les hyperthyroïdies sont exceptionnelles. Nous rapportons une nouvelle observation, originale par ses aspects physiopathologiques et sa gravité.
Un homme de 70 ans ayant une dépression unipolaire traitée depuis 2 ans par carbonate de lithium (Téralithe®) avec lithiémie à 0,5 mmol/l (N = 0,3-0,9) et clomipramine (Anafranil®) 150 mg/j, a consulté pour une hyperthyroïdie. Celle-ci avait été suspectée devant une altération de l'état général avec asthénie, sueurs et amaigrissement (10 kg en 2 mois). L'hyperthyroïdie était confirmée par le bilan hormonal : TSH = 0,01 mUI/l (N = 0,2-0,4) et T4 libre = 52 pmol/l (N = 10-25). Ce bilan réalisé 18 mois auparavant était normal. Il n'existait pas d'antécédent personnel ni familial de dysthyroïdie. On ne retrouvait pas de prise médicamenteuse iodée ni d'examen complémentaire avec produit de contraste. Le patient ne se plaignait pas de cervicalgie et était apyrétique. La vitesse de sédimentation était normale (24 mm). Le traitement par lithium était alors arrêté. Un mois après, on ne notait pas d'amélioration clinique franche : poids stable mais sueurs persistantes ; ce que confirmait le bilan biologique : TSH =0,02 mUI/l ; T4 libre= 44 pmol/l; T3 libre = 9 pmol/l (N=2-8). La thyroglobuline était à 45 µg/l (N
Translation - English Lithium-induced thyroid side effects are frequent: goitre, hypothyroidism. In contrast, hyperthyroidism is exceptional. We report on a new observation that is novel in terms of its physiopathological aspects and its severity.
A 70-year-old man with unipolar depression treated with lithium carbonate (Teralithe®) for 2 years with lithaemia at 0.5 mmol/l (N = 0.3–0.9) and clomipramine (Anafranil®) 150 mg/day, consulted due to hyperthyroidism. The latter had been suspected in view of changes to his general state of health with asthenia, sweats and weight loss (10 kg in 2 months). The hyperthyroidism was confirmed by the hormone assay: TSH = 0.01 mIU/l (N = 0.2–0.4) and free T4 = 52 pmol/l (N = 10–25). This assay was normal when done 18 months previously. There was no personal or familial history of dysthyroidism. We found no evidence of taking iodized medication or supplementary examinations with contrast medium. The patient did not complain of neck pain and was apyretic. The sedimentation rate was normal (24 mm/h). Treatment with lithium was therefore stopped. One month later, there was no significant clinical improvement: weight stable but still persistent sweats. This was confirmed by the laboratory workup: TSH = 0.02 mIU/l; free T4 = 44 pmol/l; free T3 = 9 pmol/l (N = 2–8). Thyroglobulin was at 45 µg/l (N < 40). The antimicrosomal antibody screen was negative and the antithyroglobulin antibodies were weakly positive at 1:320 (passive haemagglutination). The normal total iodaemia (8 µg/100 ml; N = 4–8) contrasted with a slightly elevated 24-h ioduria (500 µg/24 h; N = 60–150). Technetium thyroid scintigraphy showed very weak fixation. Cervical echography, not done previously, evidenced a multinodular goitre. Treatment with carbimazole (Neo-Mercazole®) at 30 mg/day and propranolol (Avlocardyl®) at 40 mg/day was introduced. The patient died 6 weeks later of a myocardial infarction. The free T4 was 32 pmol/l.
I am currently looking to register with translation agencies based in the UK and
EU offering regular translation jobs in the fields of medicine and biological
sciences and who work with Trados Studio.
In the 1970s, I lived in Luxembourg and attended the local
primary school in the village of Sandweiler. It was here that I began learning
French, German and Luxembourgish at the age of six. Back in the United Kingdom,
I passed the Institute of Linguists' diploma in both French and German with
distinction in 1986. A year later, I passed with distinction the Institute of
Linguists' translators' diploma in both French and German, specialising in
natural and exact sciences.
Always having had an interest in science and medicine, I enrolled in an
undergraduate degree course at the University of Aberdeen in 1987. I now hold
an upper second-class honours degree in microbiology and genetics and I gained
a Ph.D. in virology from the University of Cambridge in 1996. I went on to work
as a postdoctoral research scientist at the Medical Research Council Virology
Unit and at the University of Leicester.
In 2009, I took the decision to become a freelance translator, combining my
language skills with my extensive medical and scientific background.
I have over a decade of experience in translating scientific
and medical documents, including:
·Clinical trial applications, protocols
and reports
·Informed consent forms
·Summaries of product
characteristics (full prescribing information)
·Pharmacovigilance/SAE reports
·medical, clinical and surgical
reports
·Pharmaceutical manufacturing
documents, including: standard operating procedures, production processes, analytical
procedures, quality control, packaging and labelling
·Case studies and research articles
Rest assured that I am fully qualified and committed to providing you with accurate
and faithful translations of your medical and scientific texts.
This user has earned KudoZ points by helping other translators with PRO-level terms. Click point total(s) to see term translations provided.
Expertise 
